Drug Profile
Friulimicin B
Alternative Names: Friulimicin; Friulimycin B; Lipopeptide - Merlion PharmaceuticalsLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Aventis Pharmaceuticals
- Developer MerLion Pharmaceuticals
- Class Antibacterials; Lipopeptides
- Mechanism of Action Bacterial polysaccharide inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Nosocomial infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Nosocomial-infections in Singapore (Topical)
- 05 Jan 2011 Friulimicin B is available for licensing as of 05 Jan 2011. http://www.merlionpharma.com/
- 05 Jan 2011 Preclinical trials in Nosocomial infections in Singapore (Topical)